20R-Ginsenoside Rg2CAS# 80952-72-3 |
| Cas No. | 80952-72-3 | SDF | File under preparation. |
| PubChem ID | 157711 | Appearance | Powder |
| Formula | C42H72O13 | M.Wt | 785.02 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-2-[[(6R,8R,10R,12S,14S,17R)-3,12-dihydroxy-17-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol | ||
| SMILES | CC1C(C(C(C(O1)OC2C(C(C(OC2OC3CC4(C(CC(C5C4(CCC5C(C)(CCC=C(C)C)O)C)O)C6(C3C(C(CC6)O)(C)C)C)C)CO)O)O)O)O)O | ||
| Standard InChIKey | AGBCLJAHARWNLA-TZTDDQMKSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Description | Ginsenoside Rg2 may have a therapeutic potential for type 2 diabetic patients, it suppresses the hepatic glucose production via AMPK-induced phosphorylation of GSK3βand induction of SHP gene expression .Ginsenoside Rg2 can protect H9c2 cells against H2O2- induced injury through its actions of anti-oxidant and anti-apoptosis.20R-Ginsenoside Rg2 inhibits the cytokine interleukin 1 alpha (IL-1α)-induced reduction in gap junction-mediated intercellular communication (GJIC). |
| Targets | GSK-3 | IL Receptor | AMPK |
| In vitro | Effects of ginsenosides from Panax ginseng on cell-to-cell communication function mediated by gap junctions.[Pubmed: 11488454 ]Planta Med., 2001, 67(5):417-22.
|
20R-Ginsenoside Rg2 Dilution Calculator
20R-Ginsenoside Rg2 Molarity Calculator
-
Ginsenoside Rg2Catalog No.: BCN1067CAS No.: 52286-74-5 -
Ginsenoside RfCatalog No.: BCN1075CAS No.: 52286-58-5 -
(20R)-Ginsenoside Rh1Catalog No.: BCN3700CAS No.: 80952-71-2 -
Ginsenoside Rh1Catalog No.: BCN1069CAS No.: 63223-86-9 -
Ginsenoside ReCatalog No.: BCN1073CAS No.: 52286-59-6 -
Vitexin argininateCatalog No.: BCC8179CAS No.: 51542-56-4 -
20(R)-Notoginsenoside R2Catalog No.: BCN3864CAS No.: 948046-15-9 -
Notoginsenoside R2Catalog No.: BCN3328CAS No.: 80418-25-3 -
Notoginsenoside NCatalog No.: BCX1104CAS No.: 350586-56-0 -
Ginsenoside Rg1Catalog No.: BCN1066CAS No.: 22427-39-0 -
Ginsenoside Rg6Catalog No.: BCN2706CAS No.: 147419-93-0 -
Ginsenoside F4Catalog No.: BCN2881CAS No.: 181225-33-2 -
Notoginsenoside R1Catalog No.: BCN1097CAS No.: 80418-24-2 -
Gynosaponin ICatalog No.: BCN4078CAS No.: 1207861-69-5 -
Notoginsenoside MCatalog No.: BCX1105CAS No.: 394246-74-3 -
Pseudoginsenoside F11Catalog No.: BCN1062CAS No.: 69884-00-0 -
20(R)-Ginsenoside Rg3Catalog No.: BCN5018CAS No.: 38243-03-7 -
Ginsenoside Rg3Catalog No.: BCN1068CAS No.: 14197-60-5 -
Pseudoginsenoside Rh1Catalog No.: BCX1076CAS No.: 97744-96-2 -
Ginsenoside F1Catalog No.: BCN1244CAS No.: 53963-43-2 -
Vinaginsenoside R4Catalog No.: BCN8659CAS No.: 156009-80-2 -
Ginsenoside Rk3Catalog No.: BCN3502CAS No.: 364779-15-7 -
20(R)-Ginsenoside Rh2Catalog No.: BCN2484CAS No.: 112246-15-8 -
20(S)-Ginsenoside Rh2Catalog No.: BCN1070CAS No.: 78214-33-2 -
Ginsenoside Rh4Catalog No.: BCN3503CAS No.: 174721-08-5 -
Notoginsenoside T5Catalog No.: BCN3727CAS No.: 769932-34-5 -
Ginsenoside Rs3Catalog No.: BCN3716CAS No.: 194861-70-6 -
Notoginsenoside Ft1Catalog No.: BCN6434CAS No.: 155683-00-4 -
Ginsenoside F5Catalog No.: BCN6419CAS No.: 189513-26-6
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.2739 mL | 6.3693 mL | 12.7385 mL | 25.4771 mL | 31.8463 mL |
| 5 mM | 0.2548 mL | 1.2739 mL | 2.5477 mL | 5.0954 mL | 6.3693 mL |
| 10 mM | 0.1274 mL | 0.6369 mL | 1.2739 mL | 2.5477 mL | 3.1846 mL |
| 50 mM | 0.0255 mL | 0.1274 mL | 0.2548 mL | 0.5095 mL | 0.6369 mL |
| 100 mM | 0.0127 mL | 0.0637 mL | 0.1274 mL | 0.2548 mL | 0.3185 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
- (20R)-Ginsenoside Rh1
Catalog No.:BCN3700
CAS No.:80952-71-2
- Zingibroside R1
Catalog No.:BCN3433
CAS No.:80930-74-1
- Gnetumontanin B
Catalog No.:BCN3756
CAS No.:809237-87-4
- Concanamycin A
Catalog No.:BCC3919
CAS No.:80890-47-7
- 3,22-Dihydroxyolean-12-en-29-oic acid
Catalog No.:BCN1347
CAS No.:808769-54-2
- Pyracrenic acid
Catalog No.:BCN7455
CAS No.:80832-44-6
- FG-4592 (ASP1517)
Catalog No.:BCC2227
CAS No.:808118-40-3
- 1-Hydroxycanthin-6-one
Catalog No.:BCN4347
CAS No.:80787-59-3
- 3-Acetylyunaconitine
Catalog No.:BCN7640
CAS No.:80787-51-5
- Tectorigenin sodium sulfonate
Catalog No.:BCN8161
CAS No.:807636-25-5
- S-2-Benzothiazolyl2-amino-alpha-(methoxyimino)-4-thiazolethiolacetate
Catalog No.:BCC9138
CAS No.:80756-85-0
- H-Arg(Mtr)-OH.1/2H2O
Catalog No.:BCC2863
CAS No.:80745-10-4
- 6-Amino-1-naphthalenesulfonic acid
Catalog No.:BCC8758
CAS No.:81-05-0
- Musk ketone
Catalog No.:BCN8357
CAS No.:81-14-1
- 2-Amino-1-naphthalenesulfonic acid
Catalog No.:BCC8519
CAS No.:81-16-3
- Taurocholic acid
Catalog No.:BCN6954
CAS No.:81-24-3
- Cholic acid
Catalog No.:BCN1286
CAS No.:81-25-4
- Sennoside A
Catalog No.:BCN1002
CAS No.:81-27-6
- Purpurin
Catalog No.:BCN3477
CAS No.:81-54-9
- Warfarin
Catalog No.:BCC5221
CAS No.:81-81-2
- Rhodamine B
Catalog No.:BCN7215
CAS No.:81-88-9
- 4-Hydroxy-4-(methoxycarbonylmethyl)cyclohexanone
Catalog No.:BCN1346
CAS No.:81053-14-7
- Methyl 4-prenyloxycinnamate
Catalog No.:BCN7520
CAS No.:81053-49-8
- EUK 134
Catalog No.:BCC4317
CAS No.:81065-76-1
Effects of ginsenosides from Panax ginseng on cell-to-cell communication function mediated by gap junctions.[Pubmed:11488454]
Planta Med. 2001 Jul;67(5):417-22.
Gap junctions have been shown or are believed to be involved in the pathogenesis of many inherited and acquired human diseases. Agents that regulate the gap junction-mediated intercellular communication (GJIC) function may facilitate prevention and treatment of GJIC-involved diseases. In the present study we examined the effects of 27 ginsenosides isolated from Panax ginseng on GJIC. The results show that compounds 1 (oleanolic acid), 2 (ginsenoside-R0), 3 (ginsenoside-Rb1), 5 (ginsenoside-Rb2), 7 (ginsenoside-Rd), 8 (ginsenoside-Rg3), 12 (panaxadial), 13 (notoginsenoside-R4), 17 [ginsenoside-Rg2 (20S)], 18 (ginsenoside-Rf), and 26 (ginsenoside-F3) did not obviously affect GJIC, whereas compounds 4 (ginsenoside-Rc), 6 (ginsenoside-Rb3), 9 (ginsenoside-Rd2), 10 (notoginsenoside-Fe), 11 (ginsenoside-Rh2),14 (ginsenoside-Ra1), 15 (ginsenoside-Re), 16 [ginsenoside-Rg2 (20R)], 19 (ginsenoside-Ia), 20 [ginsenoside-Rh1 (20S)], 21 [ginsenoside-Rh1 (20R)], 22 (ginsenoside-F1), 23 (protopanaxatriol), 24 (panaxatriol), 25 (ginsenoside-Rg1), and 27 (chikusetsaponin-L8) induced GJIC reductions at various degrees. Compounds 2, 7, and 8 protected against the tyrosine phosphatase inhibitor vanadate-induced GJIC reduction, while compounds 1, 5, 7, and 17 inhibited the cytokine interleukin 1 alpha (IL-1alpha)-induced reduction in GJIC. Nevertheless, no compounds protected against the protein kinase C (PKC) activator 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced GJIC inhibition. On the other hand, GJIC reductions induced by compounds 6, 9,10, 20, 21, 22, 24, and 25 were inhibited by the tyrosine kinase (TK) inhibitor genistein, while GJIC reductions induced by compounds 6, 9, 14, 16, 19, 21, and 24 were attenuated in the presence of the PKC inhibitor calphostin C. However, GJIC reductions induced by compounds 4, 23, and 27 were not inhibited either by genistein or by calphostin C. These data indicate that various mechanisms are responsible for effects of ginsenosides on GJIC.
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
